Ocugen, Inc.
$1.85
0%
2026-04-21 08:35:00
www.ocugen.com
NCM: OCGN
Explore Ocugen, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$606.61 M
Current Price
$1.85
52W High / Low
$2.73 / $0.64
Stock P/E
—
Book Value
$-0.04
Dividend Yield
—
ROCE
-307.31%
ROE
-7.77%
Face Value
—
EPS
$-0.23
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
116
Beta
2.81
Debt / Equity
-2.72
Current Ratio
1.06
Quick Ratio
1.06
Forward P/E
40
Price / Sales
130.77
Enterprise Value
$591.67 M
EV / EBITDA
-9.67
EV / Revenue
134.07
Rating
Strong Buy
Target Price
$11.57
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Geron Corporation | $1.56 | — | $1.02 B | — | -11.23% | -32.99% | $2.01 / $1.04 | $0.35 |
| 2. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 3. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
| 4. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
| 5. | GRI Bio, Inc. | $2.51 | — | $3.68 M | — | -198.85% | -2.38% | $80.36 / $2.1 | $12.07 |
| 6. | Inhibrx Biosciences, Inc. | $82.39 | — | $1.29 B | — | -119.83% | -1.98% | $94.56 / $10.84 | $0.55 |
| 7. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | -0.19 M | 1.75 M | 1.37 M | 1.48 M | 0.76 M |
| Operating Profit | -17 M | -17.62 M | -13.79 M | -14.5 M | -13.84 M |
| Net Profit | -17.71 M | -20.05 M | -14.74 M | -15.35 M | -13.88 M |
| EPS in Rs | -0.05 | -0.06 | -0.04 | -0.05 | -0.04 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.41 M | 4.05 M | 6.04 M | 2.49 M |
| Operating Profit | -62.92 M | -54.76 M | -65.53 M | -89.07 M |
| Net Profit | -67.85 M | -54.05 M | -63.08 M | -86.8 M |
| EPS in Rs | -0.21 | -0.16 | -0.19 | -0.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 43.52 M | 82.44 M | 64.55 M | 108.63 M |
| Total Liabilities | 55.68 M | 52.81 M | 23.98 M | 34.65 M |
| Equity | -12.17 M | 29.63 M | 40.56 M | 73.98 M |
| Current Assets | 24.34 M | 61.68 M | 42.97 M | 98.49 M |
| Current Liabilities | 23.04 M | 21.59 M | 17.09 M | 28.53 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -56.96 M | -42.14 M | -62.05 M | -60.08 M |
| Investing CF | -0.31 M | -3.38 M | 3.08 M | -16.97 M |
| Financing CF | 17.33 M | 64.86 M | 20.88 M | 59.48 M |
| Free CF | -57.15 M | -45.53 M | -72.53 M | -64.54 M |
| Capex | -0.18 M | -3.38 M | -10.48 M | -4.46 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -32.82% | 142.6% | — | — |
| Earnings Growth % | 14.31% | 27.33% | — | — |
| Profit Margin % | -1333.02% | -1045.03% | -3488.91% | — |
| Operating Margin % | -1350.36% | -1085.67% | -3580.02% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1267.52% | -1074.01% | -3560.73% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.